课题基金 / 基金详情

UPCC 5196:PHASE I TRIAL W/ TALL 104 CELLS FOR THERAPY OF METASTATIC BREAST CANCER

UPCC 5196:PHASE I TRIAL W/ TALL 104 CELLS FOR THERAPY OF METASTATIC BREAST CANCER
UPCC 5196:使用 TALL 104 细胞治疗转移性乳腺癌的 I 期试验
批准号:
6263598
负责人:
DAVID L PORTER
金额:
$2.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

DAVID L PORTER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to evaluate the effect of TALL-104 cells in patients with metastatic breast cancer, and to study the side effects and toxic dose levels of these cells. In order to do this, varying doses of TALL- 104 cells will be given to volunteers with metastatic breast cancer. The first women involved in this trial will be given a low dose of TALL-104 cells. If no significant side effects occur, the next group of volunteers will receive a higher dose, and this "dose escalation" will continue until either 1) a dose is identified that causes too many side effects or 2) the dose has been increased 4 tims to the highest dose to be used in this study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.
  • 批准号:
    10245063
  • 项目类别:
  • 资助金额:
    $41.59万
  • 财政年份:
    2017
  • 负责人:
    DAVID L PORTER
  • 依托单位:
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.
  • 批准号:
    9982243
  • 项目类别:
  • 资助金额:
    $34.05万
  • 财政年份:
    2017
  • 负责人:
    DAVID L PORTER
  • 依托单位:
Mid-career investigator award in allogeneic adoptive immunotherapy
  • 批准号:
    7139409
  • 项目类别:
  • 资助金额:
    $15.56万
  • 财政年份:
    2006
  • 负责人:
    DAVID L PORTER
  • 依托单位:
Mid-career investigator award in allogeneic adoptive immunotherapy
  • 批准号:
    7650292
  • 项目类别:
  • 资助金额:
    $15.56万
  • 财政年份:
    2006
  • 负责人:
    DAVID L PORTER
  • 依托单位:
海外基金